Post-protocol therapy and informative censoring in the CANDOR study - Authors' reply
- PMID: 35240099
- DOI: 10.1016/S1470-2045(22)00077-8
Post-protocol therapy and informative censoring in the CANDOR study - Authors' reply
Conflict of interest statement
SZU reports grants and personal fees from Amgen, AbbVie, Bristol Myers Squibb, Celgene, Sanofi, Seattle Genetics, Janssen, Takeda, SkylineDX, Merck, and GlaxoSmithKline; personal fees from AbbVie, MundiPharma, SecuraBio, Gilead, Genentech, and Oncopeptides; and grants from Bristol Myers Squibb and Pharmacyclics. CL and MO report employment with and stockholdings of Amgen. MD reports consulting fees from Janssen, Amgen, Bristol-Myers Squibb, Takeda, and Beigene; payment or honoraria for speakers bureaus from Beigene, Janssen, Amgen, Bristol-Myers Squibb, and Takeda; and grants or contracts from Bristol-Myers Squibb, Janssen, Amgen, Takeda, and Beigene. The CANDOR study was supported by Amgen. Valerie Hilliard (Amgen) provided medical writing and editorial assistance for this work.
Comment on
-
Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): updated outcomes from a randomised, multicentre, open-label, phase 3 study.Lancet Oncol. 2022 Jan;23(1):65-76. doi: 10.1016/S1470-2045(21)00579-9. Epub 2021 Dec 3. Lancet Oncol. 2022. PMID: 34871550 Clinical Trial.
-
Post-protocol therapy and informative censoring in the CANDOR study.Lancet Oncol. 2022 Mar;23(3):e97. doi: 10.1016/S1470-2045(22)00075-4. Lancet Oncol. 2022. PMID: 35240098 No abstract available.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
